Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | PTPRC | P08575 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11667243 | 0.98 | CHEK1 (0.97) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL11547694 | 0.92 | CHEK1 (0.84) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL14199812 | 0.92 | CHEK1 (0.84) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL11632576 | 0.90 | CHEK1 (0.82) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| Monoethanolamine SCHEMBL11634327 | 0.90 | CHEK1 (0.82) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL10626360 | 0.89 | CHEK1 (0.79) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5798092 | 0.88 | CHEK1 (0.78) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL10850538 | 0.86 | KMT2A (1.00) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL3386406 | 0.86 | CHEK1 (0.75) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL14414742 | 0.86 | CHEK1 (0.75) | CHEK1KMT2AMEN1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187770-B2 | High performance, crosslinked polymeric material for holographic data storage | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-29 | — | — | US | claimed |
| US-20090104561-A1 | High performance, crosslinked polymeric material for holographic data storage | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-4737514-A | Method for treating depression with thioxanthen-9-one derivatives | BURROUGHS WELLCOME CO. (US) | 1988-04-12 | — | — | US | claimed |
| EP-0150891-A1 | Tricyclic compounds, processes for their preparation, compositions containing such compounds and their use in medicine | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-08-07 | — | — | EP | claimed |
| US-10711027-B2 | DNA polymerase beta inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-10363733-B2 | Photosensitive resin composition, planographic printing plate precursor, method for producing planographic printing plate, and polymer compound | FUJIFILM CORPORATION (JP) | 2019-07-30 | — | — | US | disclosed |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-07-04 | — | — | US | disclosed |
| US-20170173938-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PLANOGRAPHIC PRINTING PLATE PRECURSOR, METHOD FOR PRODUCING PLANOGRAPHIC PRINTING PLATE, AND POLYMER COMPOUND | FUJIFILM CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170173938-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PLANOGRAPHIC PRINTING PLATE PRECURSOR, METHOD FOR PRODUCING PLANOGRAPHIC PRINTING PLATE, AND POLYMER COMPOUND | FUJIFILM CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4737514-A | Method for treating depression with thioxanthen-9-one derivatives | BURROUGHS WELLCOME CO. (US) | 1988-04-12 | — | — | US | disclosed |
| US-4623656-A | Method for inhibiting monoamine oxidase-A and treating depression by administering 3-N-methyl-thioxanthen-9-one carboxamide 10,10-dioxide | BURROUGHS WELLCOME CO. | 1986-11-18 | — | — | US | disclosed |
| EP-0150891-A1 | Tricyclic compounds, processes for their preparation, compositions containing such compounds and their use in medicine | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-08-07 | — | — | EP | disclosed |
| US-4177257-A | ANTIANAPHYLACTIC AGENTS | BURROUGHS WELLCOME CO. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4145350-A | ANTIALLERGENS, TETRAZOLYL- SUBSTITUTED | BURROUGHS WELLCOME CO. (US) | 1979-03-20 | — | — | US | disclosed |
| US-4103015-A | TRICYCLIC THIOXANTHONE-10,10-DIOXIDES | BURROUGHS WELLCOME CO. (US) | 1978-07-25 | — | — | US | disclosed |
| US-3905989-A | USEFUL IN TREATMENT OF ALLERGIES | BURROUGHS WELLCOME CO | 1975-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | CHEK1 4100/4885KMT2A 3377/4885MEN1 2928/4885 |
| US-10711027-B2 | DNA polymerase beta inhibitors | POLB, POLH, POLN | CHEK1 88/4885KMT2A 2832/4885MEN1 4060/4885 |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | POLB, POLH, POLN | CHEK1 88/4885KMT2A 2832/4885MEN1 4060/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CHEK1 4352/4885KMT2A 3886/4885MEN1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.